Quality customer data is foundational to commercial operations, and yet most European life sciences companies are not getting what they need from their customer data. …
The common aims of early-phase research centre around helping to define the safety, tolerability and pharmacokinetics of a drug at single or multiple doses (or …
To Get the Most Out of Investigative Sites, Go After the Low-hanging Fruit In today’s clinical development arena, clinical trial sponsors are expected to achieve …
As the old adage goes, if you keep doing the same things it can’t come as a surprise when the outcome doesn’t improve. Organising data …
Growth forecasts for the global biopharmaceuticals market vary, but headline figures of close to USD 300 billion by the year 2021, rising from an estimated …
Developing an innovative healthcare product (a drug or a biologic, or a medical device) from the proof-of- concept stage to the marketing stage is an …
When we look at the emerging and likely future battles being fought to establish dominance in the emerging field of CRISPR technologies, it may be …
The North of England’s profile as a hub of health science has been on an impressive trajectory over the past five years. With some of …
Small and medium-sized enterprises (SMEs) are often faced with the challenge of having limited resources which can impact their ability to seamlessly move products through …
The life sciences industry is currently facing unprecedented turmoil. Peter Muller of Schlafender Hase outlines five trends pharma companies will need to weather in 2017, …
IPI was established by professionals with over 30 years of experience in the Pharmaceutical and Life sciences publishing sectors. Peer-Reviewed, Contemporary, Authoritative
